Understanding and Managing Persistent Activity in Wet AMD


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Indications and Usage

Visudyne® (verteporfin for injection) is indicated for the treatment of predominantly classic subfoveal choroidal neovascularization due to age-related mascular degeneration, pathlogic myopia, or presumed ocular histoplasmosis.

There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization.

Important Safety Information

  • Visudyne® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any of its components.
  • Avoid exposure of skin and eyes to direct sunlight or bright indoor light for 5 days. If extravasation occurs during infusion, the extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of a local burn which could be severe. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
  • Patients who experience severe vision decrease (≥4 lines within 1 week) should not be retreated until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered.
  • Use of incompatible lasers that do not provide the required characteristics of light for photoactivation of Visudyne could result in incomplete treatment due to partial photoactivation or overtreatment due to overactivation, or damage to surrounding normal tissue.
  • For injection of Visudyne, avoid small hand veins in favor of the largest possible arm vein, preferably the antecubital vein.
  • The most frequently reported adverse events (10% to 30% incidence) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including scotoma).

Visudyne is a registered trademark of Novartis AG used under license.
Bausch + Lomb is a trademark of Bausch & Lomb Incoporated or its affiliates.
©Bausch & Lomb Incorporated.